Evaluating the potential of NANOG as a glioma malignancy biomarker

Research output: Contribution to journalConference articlepeer-review

1 Citation (Scopus)


To elucidate the role of NANOG in malignancy, the difference in relative expression of NANOG between low-and high-grade gliomas was evaluated. Gene quantification was performed using real-time reverse transcription polymerase chain reaction from 29 isolated RNA samples of glioma resected during the surgery of patients in the Neurosurgery Department of FKUI-RSCM. The relative expression of NANOG in low-and high-grade gliomas was analyzed for normality and compared statistically. Statistical analysis showed no significant difference in NANOG expression between low-and high-grade glioma although there was a tendency for higher expression in the latter. The results support the indication of NANOG as a malignancy biomarker. However, further studies of NANOG expression in malignancy using a greater sample size or other methods may help confirm its role as a cancer biomarker that could be used as a potential therapeutic target or prognosis indicator.

Original languageEnglish
Article number032057
JournalJournal of Physics: Conference Series
Issue number3
Publication statusPublished - 7 Sept 2018
Event2nd Physics and Technologies in Medicine and Dentistry Symposium, PTMDS 2018 - Depok, West Java, Indonesia
Duration: 18 Jul 201818 Jul 2018


Dive into the research topics of 'Evaluating the potential of NANOG as a glioma malignancy biomarker'. Together they form a unique fingerprint.

Cite this